-
1
-
-
0002074953
-
-
Köln, Second International Conference on Biology, Prevention and Treatment of GI Malignancies
-
Scheithauer W, Kornek G, Zeh B: Palliative chemotherapy versus best supportive care in patients with metastatic gastric cancer: a randomized trial. Köln, Second International Conference on Biology, Prevention and Treatment of GI Malignancies, 1995, p 68.
-
(1995)
Palliative Chemotherapy Versus Best Supportive Care in Patients with Metastatic Gastric Cancer: A Randomized Trial
, pp. 68
-
-
Scheithauer, W.1
Kornek, G.2
Zeh, B.3
-
2
-
-
0027217474
-
Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer
-
Murad AM, Santiago FF, Petroianu A, Rocha P, Rodrigues M, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
-
(1993)
Cancer
, vol.72
, pp. 37-41
-
-
Murad, A.M.1
Santiago, F.F.2
Petroianu, A.3
Rocha, P.4
Rodrigues, M.5
Rausch, M.6
-
3
-
-
0028959887
-
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer
-
Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Brit J Cancer 1995; 71: 587-591.
-
(1995)
Brit J Cancer
, vol.71
, pp. 587-591
-
-
Pyrhönen, S.1
Kuitunen, T.2
Nyandoto, P.3
Kouri, M.4
-
4
-
-
8044236424
-
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer
-
Glimelius B, Ekström K, Hoffmann K, Graf W, Sjöden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellström H, Heumann R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168.
-
(1997)
Ann Oncol
, vol.8
, pp. 163-168
-
-
Glimelius, B.1
Ekström, K.2
Hoffmann, K.3
Graf, W.4
Sjöden, P.O.5
Haglund, U.6
Svensson, C.7
Enander, L.K.8
Linne, T.9
Sellström, H.10
Heumann, R.11
-
5
-
-
26444529508
-
Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): Benefit dependent on progression-free interval after first-line therapy
-
Stahl M, Muller C, Koster W, Wilke H: Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy. Onkologie 2005; 28: 499-502.
-
(2005)
Onkologie
, vol.28
, pp. 499-502
-
-
Stahl, M.1
Muller, C.2
Koster, W.3
Wilke, H.4
-
6
-
-
14644421555
-
Review of secondline chemotherapy for advanced gastric adenocarcinoma
-
Wilson D, Hiller L, Geh JI: Review of secondline chemotherapy for advanced gastric adenocarcinoma. Clin Oncol 2005; 17: 81-90.
-
(2005)
Clin Oncol
, vol.17
, pp. 81-90
-
-
Wilson, D.1
Hiller, L.2
Geh, J.I.3
-
7
-
-
0742271770
-
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma
-
Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Normann AR: Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004; 15: 64-69.
-
(2004)
Ann Oncol
, vol.15
, pp. 64-69
-
-
Assersohn, L.1
Brown, G.2
Cunningham, D.3
Ward, C.4
Oates, J.5
Waters, J.S.6
Hill, M.E.7
Normann, A.R.8
-
8
-
-
0038004543
-
Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed
-
Schmidt KE, Kornek GV, Schüll B, Raderer M, Lenauer A, Depisch D, Lange F, Scheithauer W: Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed Onkologie 2003; 26: 255-258
-
(2003)
Onkologie
, vol.26
, pp. 255-258
-
-
Schmidt, K.E.1
Kornek, G.V.2
Schüll, B.3
Raderer, M.4
Lenauer, A.5
Depisch, D.6
Lange, F.7
Scheithauer, W.8
-
9
-
-
80053341349
-
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
-
Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47: 2306-2314.
-
(2011)
Eur J Cancer
, vol.47
, pp. 2306-2314
-
-
Thuss-Patience, P.C.1
Kretzschmar, A.2
Bichev, D.3
Deist, T.4
Hinke, A.5
Breithaupt, K.6
Dogan, Y.7
Gebauer, B.8
Schumacher, G.9
Reichardt, P.10
-
10
-
-
84862981823
-
Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone
-
Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH: Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30: 1513-1518.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1513-1518
-
-
Kang, J.H.1
Lee, S.I.2
Lim Do, H.3
Park, K.W.4
Oh, S.Y.5
Kwon, H.C.6
Hwang, I.G.7
Lee, S.C.8
Nam, E.9
Shin, D.B.10
Lee, J.11
Park, J.O.12
Park, Y.S.13
Lim, H.Y.14
Kang, W.K.15
Park, S.H.16
-
11
-
-
0037263849
-
Gastric cancer epidemiology and risk factors
-
Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56: 1-9.
-
(2003)
J Clin Epidemiol
, vol.56
, pp. 1-9
-
-
Kelley, J.R.1
Duggan, J.M.2
-
12
-
-
0037295092
-
Chemotherapy in gastric cancer: A never ending saga
-
Roth AD: Chemotherapy in gastric cancer: a never ending saga. Ann Oncol 2003; 14: 175-177.
-
(2003)
Ann Oncol
, vol.14
, pp. 175-177
-
-
Roth, A.D.1
-
13
-
-
0036015227
-
Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: Efficacy of therapy and value of serum tumor markers
-
Schulze-Bergkamen H, Zuna I, Teufel A, Stremmel W, Rudi J: Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers. Med Oncol 2002; 19: 43-53.
-
(2002)
Med Oncol
, vol.19
, pp. 43-53
-
-
Schulze-Bergkamen, H.1
Zuna, I.2
Teufel, A.3
Stremmel, W.4
Rudi, J.5
-
14
-
-
84859842052
-
Prognostic factors of second and third line chemotherapy using 5-FU with platinum, irinotecan, and taxane for advanced gastric cancer
-
Park JS, Lim JY, Park SK, Kim MK, Ko HS, Yoon SO, Kim JW, Choi SH, Cho JY: Prognostic factors of second and third line chemotherapy using 5-FU with platinum, irinotecan, and taxane for advanced gastric cancer. Cancer Res Treat 2011; 43: 236-243.
-
(2011)
Cancer Res Treat
, vol.43
, pp. 236-243
-
-
Park, J.S.1
Lim, J.Y.2
Park, S.K.3
Kim, M.K.4
Ko, H.S.5
Yoon, S.O.6
Kim, J.W.7
Choi, S.H.8
Cho, J.Y.9
-
15
-
-
77956262693
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
-
ToGA Trial Investigators
-
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
-
(2010)
Lancet
, vol.376
, pp. 687-697
-
-
Bang, Y.J.1
Van Cutsem, E.2
Feyereislova, A.3
Chung, H.C.4
Shen, L.5
Sawaki, A.6
Lordick, F.7
Ohtsu, A.8
Omuro, Y.9
Satoh, T.10
Aprile, G.11
Kulikov, E.12
Hill, J.13
Lehle, M.14
Rüschoff, J.15
Kang, Y.K.16
-
16
-
-
0012234893
-
Randomized phase II study of weekly 24h infusion of high dose 5-FU +/-folinic acid (HD-FU +/-FA) vs. HD-FU/FA/ biweekly cisplatin in advanced gastric cancer
-
Vanhoefer U, Wagener T, Lutz M, Van Cutsem E, Nordlinger B, Reuse S, Baron B, Wilke H, Wils J: Randomized phase II study of weekly 24h infusion of high dose 5-FU +/-folinic acid (HD-FU +/-FA) vs. HD-FU/FA/ biweekly cisplatin in advanced gastric cancer. Eur J Cancer 2001; 37(suppl 6):S27.
-
(2001)
Eur J Cancer
, vol.37
, pp. S27
-
-
Vanhoefer, U.1
Wagener, T.2
Lutz, M.3
Van Cutsem, E.4
Nordlinger, B.5
Reuse, S.6
Baron, B.7
Wilke, H.8
Wils, J.9
-
17
-
-
0031022803
-
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer
-
Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
-
(1997)
J Clin Oncol
, vol.15
, pp. 261-267
-
-
Webb, A.1
Cunningham, D.2
Scarffe, J.H.3
Harper, P.4
Norman, A.5
Joffe, J.K.6
Hughes, M.7
Mansi, J.8
Findlay, M.9
Hill, A.10
Oates, J.11
Nicolson, M.12
Hickish, T.13
O'brien, M.14
Iveson, T.15
Watson, M.16
Underhill, C.17
Wardley, A.18
Meehan, M.19
-
18
-
-
0037090686
-
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer
-
Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996-2004.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1996-2004
-
-
Ross, P.1
Nicolson, M.2
Cunningham, D.3
Valle, J.4
Seymour, M.5
Harper, P.6
Price, T.7
Anderson, H.8
Iveson, T.9
Hickish, T.10
Lofts, F.11
Norman, A.12
-
19
-
-
33750949065
-
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group
-
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4991-4997
-
-
Van Cutsem, E.1
Moiseyenko, V.M.2
Tjulandin, S.3
Majlis, A.4
Constenla, M.5
Boni, C.6
Rodrigues, A.7
Fodor, M.8
Chao, Y.9
Voznyi, E.10
Risse, M.L.11
Ajani, J.A.12
-
20
-
-
21644450088
-
Fluourouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first-line therapy for patients with advanced gastric cancer; First interim analysis of a randomised multicenter phase II study
-
Al-Batran S, Stöhlmacher J, Probst S, Hollerbach S, Wilhelm G, Derigs H, Seipelt G, Kojouharoff G, Graubner M, Hinke A, Jäger E: Fluourouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first-line therapy for patients with advanced gastric cancer; first interim analysis of a randomised multicenter phase II study. J Clin Oncol 2005; 23:S311.
-
(2005)
J Clin Oncol
, vol.23
, pp. S311
-
-
Al-Batran, S.1
Stöhlmacher, J.2
Probst, S.3
Hollerbach, S.4
Wilhelm, G.5
Derigs, H.6
Seipelt, G.7
Kojouharoff, G.8
Graubner, M.9
Hinke, A.10
Jäger, E.11
-
21
-
-
13244266683
-
Randomized multicenter phase II trial of biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803
-
Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsene D, Paitel JF, Guerin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C: Randomized multicenter phase II trial of biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004; 22: 4319-4328.
-
(2004)
J Clin Oncol
, vol.22
, pp. 4319-4328
-
-
Bouche, O.1
Raoul, J.L.2
Bonnetain, F.3
Giovannini, M.4
Etienne, P.L.5
Lledo, G.6
Arsene, D.7
Paitel, J.F.8
Guerin-Meyer, V.9
Mitry, E.10
Buecher, B.11
Kaminsky, M.C.12
Seitz, J.F.13
Rougier, P.14
Bedenne, L.15
Milan, C.16
-
22
-
-
22144469838
-
Randomized phase II evaluation of irinotecan plus high-dose 5-fluourouracil and leucovorin (IFL) versus 5-fluourouracil, leucovorin and etoposide (ELF) in untreated metastatic gastric cancer
-
Moehler M, Eimermacher A, Siebler J, Hohler T, Wein A, Menges M, Flieger D, Junginger T, Geer T, Gracien E, Galle PR, Heike M: Randomized phase II evaluation of irinotecan plus high-dose 5-fluourouracil and leucovorin (IFL) versus 5-fluourouracil, leucovorin and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92: 2122-2128.
-
(2005)
Br J Cancer
, vol.92
, pp. 2122-2128
-
-
Moehler, M.1
Eimermacher, A.2
Siebler, J.3
Hohler, T.4
Wein, A.5
Menges, M.6
Flieger, D.7
Junginger, T.8
Geer, T.9
Gracien, E.10
Galle, P.R.11
Heike, M.12
-
23
-
-
32944474464
-
Randomized phase III trial of irinotecan (CPT 11)-5-FU/folinic acid (FA) vs. CDDP + 5-FU in first line advanced gastric cancer patients
-
Dank M, Zaluski J, Barone C, Valvere V, Peschel C, Wenczl M, Goker E, Risse M, Awad L, Bugat R: Randomized phase III trial of irinotecan (CPT 11)-5-FU/folinic acid (FA) vs. CDDP + 5-FU in first line advanced gastric cancer patients. J Clin Oncol 2005; 23:S308.
-
(2005)
J Clin Oncol
, vol.23
, pp. S308
-
-
Dank, M.1
Zaluski, J.2
Barone, C.3
Valvere, V.4
Peschel, C.5
Wenczl, M.6
Goker, E.7
Risse, M.8
Awad, L.9
Bugat, R.10
-
24
-
-
33745547767
-
Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
-
Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2903-2909
-
-
Wagner, A.D.1
Grothe, W.2
Haerting, J.3
Kleber, G.4
Grothey, A.5
Fleig, W.E.6
-
25
-
-
2142703727
-
Survival of patients with advanced colorectal cancer improves with the availability of fluourouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment
-
Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluourouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1209-1214
-
-
Grothey, A.1
Sargent, D.2
Goldberg, R.M.3
Schmoll, H.J.4
-
26
-
-
77953231301
-
Progressionfree survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer
-
Hashimoto K, Takashima A, Nagashima K, Okazaki SS, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shimada Y: Progressionfree survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. J Cancer Res Clin Oncol 2010; 136: 1059-1064.
-
(2010)
J Cancer Res Clin Oncol
, vol.136
, pp. 1059-1064
-
-
Hashimoto, K.1
Takashima, A.2
Nagashima, K.3
Okazaki, S.S.4
Nakajima, T.E.5
Kato, K.6
Hamaguchi, T.7
Yamada, Y.8
Shimada, Y.9
-
27
-
-
80052246962
-
Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer
-
Bohanes P, Courvoisier DS, Perneger TV, Morel P, Huber O, Roth AD: Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer. Swiss Med Wkly 2011; 141:w13249.
-
(2011)
Swiss Med Wkly
, vol.141
, pp. w13249
-
-
Bohanes, P.1
Courvoisier, D.S.2
Perneger, T.V.3
Morel, P.4
Huber, O.5
Roth, A.D.6
-
28
-
-
55249120959
-
Second line chemotherapy for patients with advanced gastric cancer: Who may benefit?
-
Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E, Tonini G, Catalano G: Second line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 2008; 99: 1402-1407.
-
(2008)
Br J Cancer
, vol.99
, pp. 1402-1407
-
-
Catalano, V.1
Graziano, F.2
Santini, D.3
D'emidio, S.4
Baldelli, A.M.5
Rossi, D.6
Vincenzi, B.7
Giordani, P.8
Alessandroni, P.9
Testa, E.10
Tonini, G.11
Catalano, G.12
-
29
-
-
77956121489
-
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy
-
Kanagavel D, Pokataev IA, Fedyanin MY, Tryakin AA, Bazin IS, Narimanov MN, Yakovleva ES, Garin AM, Tjulandin SA: A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol 2010; 21: 1779-1785.
-
(2010)
Ann Oncol
, vol.21
, pp. 1779-1785
-
-
Kanagavel, D.1
Pokataev, I.A.2
Fedyanin, M.Y.3
Tryakin, A.A.4
Bazin, I.S.5
Narimanov, M.N.6
Yakovleva, E.S.7
Garin, A.M.8
Tjulandin, S.A.9
|